PubMed Health. A service of the National Library of Medicine, National Institutes of Health.

Chou R, McDonagh MS, Nakamoto E, et al. Analgesics for Osteoarthritis: An Update of the 2006 Comparative Effectiveness Review [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2011 Oct. (Comparative Effectiveness Reviews, No. 38.)

Appendix EExcluded Studies

1.
Diclofenac gel for osteoarthritis. Med Lett Drugs Ther. 2008;50(1284):31–2. Publication type not included in this review. [PubMed: 18425055]
2.
Ahmed M, Khanna D, Furst DE. Meloxicam in rheumatoid arthritis. Expert Opin Drug Metab Toxicol. 2005;1(4):739–51. Population differs from those in this review. [PubMed: 16863437]
3.
Aisen PS, Thal LJ, Ferris SH, et al. Rofecoxib in patients with mild cognitive impairment: further analyses of data from a randomized, double-blind, trial. Curr Alzheimer Res. 2008;5(1):73–82. Outcomes not included in this review. [PubMed: 18288935]
4.
Alekseeva LI. Comparative evaluation of the safety and efficacy of etoricoxib and diclofenac on the upper gastrointestinal tract in patients with osteoarthrosis and rheumatoid arthritis (the multinational etoricoxib and diclofenac arthritis long-term (MEDAL) study program) Terapevticheskii Arkhiv. 82(8):57–62. Foreign Language article. [PubMed: 20873248]
5.
Allegrini A, Nuzzo L, Pavone D, et al. Efficacy and safety of piroxicam patch versus piroxicam cream in patients with lumbar osteoarthritis. A randomized, placebo-controlled study. Arzneimittel-Forschung. 2009;59(8):403–9. Foreign Language article. [PubMed: 19813463]
6.
Altman RD. Pharmacological therapies for osteoarthritis of the hand: a review of the evidence. Drugs Aging. 2010;27(9):729–45. Publication type not included in this review. [PubMed: 20809663]
7.
Balthazar-Letawe D. Voltaren Emulgel en pratique rhumatologique. Essai comparatif avec Indocid gel. [Voltaren Emugel in clinical rheumatology. Comparative trial with Indocid gel] Acta Belg Med Phys. 1987;10:109–10. Foreign Language article. [PubMed: 2961174]
8.
Bannwarth B. Safety of the nonselective NSAID nabumetone : focus on gastrointestinal tolerability. Drug Safety. 2008;31(6):485–503. Population differs from those in this review. [PubMed: 18484783]
9.
Bannwarth B, Berenbaum F. Clinical pharmacology of lumiracoxib, a second-generation cyclooxygenase 2 selective inhibitor. Expert Opin Investig Drugs. 2005;14(4):521–33. Population differs from those in this review. [PubMed: 15882125]
10.
Bansal SS, Joshi A, Bansal AK. New dosage formulations for targeted delivery of cyclo-oxygenase-2 inhibitors: focus on use in the elderly. Drugs Aging. 2007;24(6):441–51. Outcomes not included in this review. [PubMed: 17571910]
11.
Baraf HS, Fuentealba C, Greenwald M, et al. Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: results of the Etoricoxib versus Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) trial. J Rheumatol. 2007;34(2):408–20. Outcomes not included in this review. [PubMed: 17304660]
12.
Barthel HR, Peniston JH, Clark MB, et al. Correlation of pain relief with physical function in hand osteoarthritis: randomized controlled trial post hoc analysis. Arthritis Res Ther. 2010;12(1):R7. Outcomes not included in this review. [PMC free article: PMC2875633] [PubMed: 20064249]
13.
Beaulieu AD, Peloso PM, Haraoui B, et al. Once-daily, controlled-release tramadol and sustained-release diclofenac relieve chronic pain due to osteoarthritis: a randomized controlled trial. Pain Res Manag. 2008;13(2):103–10. Outcomes not included in this review. [PMC free article: PMC2671218] [PubMed: 18443672]
14.
Benito-Garcia E, Michaud K, Wolfe F. The effect of low-dose aspirin on the decreased risk of development of dyspepsia and gastrointestinal ulcers associated to cyclooxygenase-2 selective inhibitors. J Rheumatol. 2007;34(8):1765–9. Drug not included in this review. [PubMed: 17611980]
15.
Berge HM, Gjelstad S, Furu K, et al. Use of glucosamine does not reduce the need for other pain-relieving drugs. Tidsskrift for Den Norske Laegeforening. 130(15):1463–6. Foreign Language article. [PubMed: 20706306]
16.
Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis. Rheumatology (Oxford) 2005;44(5):677–80. Outcomes not included in this review. [PubMed: 15784627]
17.
Bertagnolli MM. Chemoprevention of colorectal cancer with cyclooxygenase-2 inhibitors: two steps forward, one step back. Lancet Oncol. 2007;8(5):439–43. Population differs from those in this review. [PubMed: 17466901]
18.
Bertagnolli MM, Zauber AG, Solomon S. Prostaglandin inhibition and cardiovascular risk: maybe timing really is everything. Cancer Prev Res (Phila) 2009;2(3):195–6. Population differs from those in this review. [PubMed: 19258547]
19.
Bessette L, Risebrough N, Mittmann N, et al. Cost-utility of celecoxib use in different treatment strategies for osteoarthritis and rheumatoid arthritis from the Quebec healthcare system perspective. J Med Econ. 2009;12(3):246–58. Outcomes not included in this review. [PubMed: 19743942]
20.
Bin SI, Wu SS, Zeng X, et al. Efficacy of lumiracoxib in relieving pain associated with knee osteoarthritis: A 6-week, randomized, double-blind, parallel-group study. APLAR Journal of Rheumatology. 2007;10(3):190–7. Outcomes not included in this review.
21.
Block JA, Oegema TR, Sandy JD, et al. The effects of oral glucosamine on joint health: is a change in research approach needed. Osteoarthritis Cartilage. 2010;18(1):5–11. Publication type not included in this review. [PubMed: 19733270]
22.
Bombardier C, Laine L, Burgos-Vargas R, et al. Response to expression of concern regarding VIGOR study. N Engl J Med. 2006;354(11):1196–9. Outcomes not included in this review. [PubMed: 16495387]
23.
Boswell DJ, Ostergaard K, Philipson RS, et al. Evaluation of GW406381 for treatment of osteoarthritis of the knee: two randomized, controlled studies. MedGenMed. 2008;10(11):259. Outcomes not included in this review. [PMC free article: PMC2605121] [PubMed: 19099009]
24.
Bourgeois P, Dehais J, Delcambre B, et al. Efficacy and tolerability of chondroitin sulfate 1200 mg/day vs chondroitin sulfate 3× 400 mg/day vs placebo. Osteoarthritis Cartilage. 1998;6:25–30. Study results included through another publication. [PubMed: 9743816]
25.
Bruyere O, Burlet N, Delmas PD, et al. Evaluation of symptomatic slow-acting drugs in osteoarthritis using the GRADE system. BMC Musculoskelet Disord. 2008;9:165. Publication type not included in this review. [PMC free article: PMC2627841] [PubMed: 19087296]
26.
Bruyere O, Pavelka K, Rovati LC, et al. Total joint replacement after glucosamine sulphate treatment in knee osteoarthritis: results of a mean 8-year observation of patients from two previous 3-year, randomised, placebo-controlled trials. Osteoarthritis Cartilage. 2008;16(2):254–60. Outcomes not included in this review. [PubMed: 17681803]
27.
Cannon CP, Curtis SP, Bolognese JA, et al. Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) Study Program: Cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis. American Heart Journal. 2006;152(2):237. Outcomes not included in this review. [PubMed: 16875903]
28.
Cannon CP, Curtis SP, FitzGerald GA, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2006;368(9549) Outcomes not included in this review. [PubMed: 17113426]
29.
Castelnuovo E, Cross P, Mt-Isa S, et al. Cost-effectiveness of advising the use of topical or oral ibuprofen for knee pain;the TOIB study [ISRCTN: 79353052] Rheumatology (Oxford) 2008;47(7):1077–81. Publication type not included in this review. [PubMed: 18511476]
30.
Champion P. Re: Beaulieu AD, Peloso PM, Haraoui B, et al. Once -daily, controlled-release tramadol and sustained-release diclofenac relieve chronic pain to osteoarthritis: a randomized controlled trial. Pain Res Manage. 2008;13:103–10. [PMC free article: PMC2671321] [PubMed: 18816899]
Thorne C, Beaulieu AD, Callaghan DJ, et al. A randomized, double-blind, crossover comparison of the efficacy and safety of oral controlled-release tramadol and placebo in patients with painful osteoarthritis. Pain Res Manage. 2008;13:93–102. [PMC free article: PMC2671321] [PubMed: 18816899]
Pain Res Manag. 2008;13(4):342. Outcomes not included in this review. [PMC free article: PMC2671321] [PubMed: 18816899]
31.
Chan FKL, Cryer B, Goldstein JL, et al. A novel composite endpoint to evaluate the gastrointestinal (GI) effects of nonsteroidal antiinflammatory drugs through the entire GI tract. J Rheumatol. 2010;37(1):167–74. Publication type not included in this review. [PubMed: 19884267]
32.
Chang ST, Chen LC, Chang CC, et al. Efficacy and safety of piroxicam beta-cyclodextrin sachets for treating chronic low back pain: a randomized, parallel, active-controlled trial. J Med Sci. 2008;28(3):111–9. Drug not included in this review.
33.
Chang ST, Chen LC, Chang CC, et al. Effects of piroxicam-beta-cyclodextrin sachets on abnormal postural sway in patients with chronic low back pain. J Clin Pharm Ther. 2008;33(5):495–506. Drug not included in this review. [PubMed: 18834364]
34.
Charlot M, Ahlehoff O, Norgaard ML, et al. Proton-Pump Inhibitors Are Associated With Increased Cardiovascular Risk Independent of Clopidogrel Use. Ann Intern Med. 2010;153(6):378–86. Publication type not included in this review. [PubMed: 20855802]
35.
Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA. 2003;289(19):2560–71. Publication type not included in this review. [PubMed: 12748199]
36.
Cibere J, Kopec JA, Thorne A, et al. Randomized, double-blind, placebo-controlled glucosamine discontinuation trial in knee osteoarthritis. Arthritis Rheum. 2004;51(5):738–45. Study results included through another publication. [PubMed: 15478160]
37.
Cibere J, Thorne A, Kopec JA, et al. Glucosamine sulfate and cartilage type II collagen degradation in patients with knee osteoarthritis: randomized discontinuation trial results employing biomarkers. J Rheumatol. 2005;32(5):896–902. Outcomes not included in this review. [PubMed: 15868627]
38.
Combe B, Swergold G, McLay J, et al. Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study) Rheumatology (Oxford) 2009;48(4):425–32. Outcomes not included in this review. [PubMed: 19223284]
39.
Crofford LJ, Breyer MD, Strand CV, et al. Cardiovascular effects of selective COX-2 inhibition: is there a class effect? The International COX-2 Study Group. J Rheumatol. 2006;33(7):1403–8. Population differs from those in this review. [PubMed: 16724374]
40.
Cross PL, Ashby D, Harding G, et al. TOIB Study. Are topical or oral ibuprofen equally effective for the treatment of chronic knee pain presenting in primary care: a randomised controlled trial with patient preference study. BMC Musculoskelet Disord. 2005;6:55. Study design not included in this review. [PMC free article: PMC1314890] [PubMed: 16274477]
41.
Curfman GD, Morrissey S, Drazen JM. Expression of concern reaffirmed. N Engl J Med. 2006;354(11):1193. Population differs from those in this review. [PubMed: 16495386]
42.
Curtis SP, Bockow B, Fisher C, et al. Etoricoxib in the treatment of osteoarthritis over 52-weeks: a double-blind, active-comparator controlled trial. BMC Musculoskelet Disord. 2005;6:58. Outcomes not included in this review. [PMC free article: PMC1327669] [PubMed: 16321158]
43.
Curtis SP, Ko AT, Bolognese JA, et al. Pooled analysis of thrombotic cardiovascular events in clinical trials of the COX-2 selective Inhibitor etoricoxib. Curr Med Res Opin. 2006;22(12):2365–74. Outcomes not included in this review. [PubMed: 17265571]
44.
Cuzick J, Otto F, Baron JA, et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol. 2009;10(5):501–7. Population differs from those in this review. [PubMed: 19410194]
45.
D’Ambrosio E, Casa B, Bompani R, et al. Glucosamine sulphate: a controlled clinical investigation in arthrosis. Pharmatherapeutica. 1981;(2):504–8. Study results included through another publication. [PubMed: 7019929]
46.
Dhillon S. Tramadol/paracetamol fixed-dose combination: a review of its use in the management of moderate to severe pain. Clin Drug Invest. 2010;30(10):711–38. Publication type not included in this review. [PubMed: 20701403]
47.
Elwood PC, Gallagher AM, Duthie GG, et al. Aspirin, salicylates, and cancer. Lancet. 2009;373(9671):1301–9. Population differs from those in this review. [PubMed: 19328542]
48.
Emery P, Zeidler H, Kvien TK, et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet. 1999;354(9196):2106–11. Study results included through another publication. [PubMed: 10609815]
49.
Feldman M, McMahon AT. Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity. Ann Intern Med. 2000;132(2):134–43. Study results included through another publication. [PubMed: 10644275]
50.
Felson DT. Glucosamine and chondroitin sulfate in knee osteoarthritis: where now. Nat Clin Pract Rheumatol. 2006;2(7):356–7. Population differs from those in this review. [PubMed: 16932718]
51.
Fleischmann R, Sheldon E, Maldonado-Cocco J, et al. Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a prospective randomized 13-week study versus placebo and celecoxib. Clin Rheumatol. 2006;25(1):42–53. Drug not included in this review. [PubMed: 16132165]
52.
Fleischmann R, Tannenbaum H, Patel NP, et al. Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: a randomised controlled trial in patients with osteoarthritis. BMC Musculoskelet Disord. 2008;9:32. Outcomes not included in this review. [PMC free article: PMC2322990] [PubMed: 18328090]
53.
Florentinus SR, Heerdink ER, de Boer A, et al. The trade-off between cardiovascular and gastrointestinal effects of rofecoxib. Pharmacoepidemiol Drug Saf. 2005;14(7):437–41. Outcomes not included in this review. [PubMed: 15937867]
54.
Garner SE, Fidan D, Frankish RR, et al. Rofecoxib for rheumatoid arthritis. Cochrane Database Syst Rev. 2009. Outcomes not included in this review. [PubMed: 15674912]
55.
Geba G, Weaver AL, Polis AB, et al. Efficacy of rofecoxib, celecoxib, and acetominophen in osteoarthritis of the knee. JAMA. 2002;287(1):64–71. Study results included through another publication. [PubMed: 11754710]
56.
Ghosh S, Paul S, Das N, et al. A study on the effects of diclofenac sodium and etoricoxib in the treatment of osteoarthritis. J Indian Med Assoc. 2007;105(5):260–2. Outcomes not included in this review. [PubMed: 17915794]
57.
Giacovelli G, Rovati LC. Glucosamine and osteoarthritis Conclusions not supported by methods and results. BMJ. 2010;341:c6338. Publication type not included in this review. [PubMed: 21062886]
58.
Gibofsky A, Rodrigues J, Fiechtner J, et al. Efficacy and tolerability of valdecoxib in treating the signs and symptoms of severe rheumatoid arthritis: a 12-week, multicenter, randomized, double-blind, placebo-controlled study. Clin Ther. 2007;29(6):1071–85. Outcomes not included in this review. [PubMed: 17692722]
59.
Gierse J, Nickols M, Leahy K, et al. Evaluation of COX–1/COX-2 selectivity and potency of a new class of COX-2 inhibitors. Eur J Pharmacol. 2008;588(1):93–8. Population differs from those in this review. [PubMed: 18457826]
60.
Goldberg SH, Von Feldt JM, Lonner JH. Pharmacologic therapy for osteoarthritis. Am J Orthop. 2002;31(12):673–80. Study results included through another publication. [PubMed: 12498526]
61.
Goldstein J, Aisenberg J, Zakko S, Berger, et al. Endoscopic Ulcer Rates in Healthy Subjects Associated with Use of Aspirin (81 mg q.d.) Alone or Coadministered with Celecoxib or Naproxen: A randomized, 1-Week Trial. Dig Dis Sci. 2008;53(3):647–56. Population differs from those in this review. [PubMed: 17676393]
62.
Goldstein JL, Bello AE, Spalding W, et al. Cyclooxygenase-2 specific inhibitors and upper gastrointestinal tolerability in patients with osteoarthritis receiving concomitant low dose aspirin: pooled analysis of 2 trials. J Rheumatol. 2005;32:111–7. Outcomes not included in this review. [PubMed: 15630735]
63.
Goldstein JL, Lowry SC, Lanza FL, et al. The impact of low-dose aspirin on endoscopic gastric and duodenal ulcer rates in users of a non-selective non-steroidal anti-inflammatory drug or a cyclo-oxygenase-2-selective inhibitor. Aliment Pharmacol Ther. 2006;23(10):1489–98. Population differs from those in this review. [PubMed: 16669964]
64.
Graf J. Analgesic use in the elderly: the “pain” and simple truth: comment on “The comparative safety of analgesics in older adults with arthritis” Arch Intern Med. 2010;170(22):1976–8. Publication type not included in this review. [PubMed: 21149753]
65.
Greenberg JD, Fisher MC, Kremer J, et al. The COX-2 inhibitor market withdrawals and prescribing patterns by rheumatologists in patients with gastrointestinal and cardiovascular risk. Clin Exp Rheumatol. 2009;27(3):395–401. Population differs from those in this review. [PubMed: 19604430]
66.
Group AR, Meinert CL, McCaffrey LD, et al. Alzheimer’s Disease Anti-inflammatory Prevention Trial: design, methods, and baseline results. Alzheimer’s Dement. 2009;5(2):93–104. Study results included through another publication. [PMC free article: PMC2866447] [PubMed: 19328435]
67.
Gruenwald J, Petzold E, Busch R, et al. Effect of glucosamine sulfate with or without omega-3 fatty acids in patients with osteoarthritis. Adv Ther. 2009;26(9):858–71. Drug not included in this review. [PubMed: 19756416]
68.
Haghighi M, Khalvat A, Toliat T, et al. Comparing the effects of ginger (Zingiber officinale) extract and ibuprofen on patients with osteoarthritis. Arch Iran Med. 2005;8(4):267–71. Outcomes not included in this review.
69.
Hampton T. Arthritis clinical trial results revealed. JAMA. 2007;297(1):28–9. Population differs from those in this review. [PubMed: 17200465]
70.
Hawkey CJ, Gitton X, Hoexter G, et al. Gastrointestinal tolerability of lumiracoxib in patients with osteoarthritis and rheumatoid arthritis. Clin Gastroenterol Hepatol. 2006;4(1):57–66. Outcomes not included in this review. [PubMed: 16431306]
71.
Hawkey CJ, Weinstein WM, Smalley W, et al. Effect of risk factors on complicated and uncomplicated ulcers in the TARGET lumiracoxib outcomes study. Gastroenterology. 2007;133(1):57–64. Drug not included in this review. [PubMed: 17631131]
72.
Hawkey CJ, Weinstein WM, Stricker K, et al. Clinical trial: comparison of the gastrointestinal safety of lumiracoxib with traditional nonselective nonsteroidal anti-inflammatory drugs early after the initiation of treatment--findings from the Therapeutic Arthritis Research and Gastrointestinal Event Trial. Aliment Pharmacol Ther. 2008;27(9):838–45. Drug not included in this review. [PubMed: 18221410]
73.
Henrich W, Agodoa L, Barrett B, et al. Analgesics and the kidney: summary and recommendations to the Scientific Advisory Board of the National Kidney Foundation from an Ad Hoc Committee of the National Kidney Foundation. Am J Kidney Dis. 1996;27(1):162–65. Publication type not included in this review. [PubMed: 8546133]
74.
Herrera JA, Millan A, Ramos R, et al. Evaluation of the effectiveness and tolerability of controlled-release diclofenac-potassium versus immediate-release diclofenac-potassium in the treatment of knee osteoarthritis. Curr Ther Res Clin Exp. 2007;68(2):82–93. Drug not included in this review. [PMC free article: PMC3965968] [PubMed: 24678122]
75.
Hochberg MC, Clegg DO. Potential effects of chondroitin sulfate on joint swelling: a GAIT report. Osteoarthritis Cartilage. 2008;16(Suppl 3):S22–4. Study results included through another publication. [PMC free article: PMC3771637] [PubMed: 18768335]
76.
Hopman WM, Towheed TE, Gao Y, et al. Prevalence of and factors associated with glucosamine use in Canada. Osteoarthritis Cartilage. 2006;14(12):1288–93. Population differs from those in this review. [PubMed: 16831560]
77.
Houpt JB, McMillan R, Wein C, et al. Effect of glucosamine hydrochloride in the treatment of pain of osteoarthritis of the knee. J Rheumatol. 1999;26(11):2423–30. Study results included through another publication. [PubMed: 10555905]
78.
Hughes R, Carr A. A randomized, double-blind, placebo-controlled trial of glucosamine sulphate as an analgesic in osteoarthritis of the knee. Rheumatology (Oxford) 2002;41(3):279–84. Study results included through another publication. [PubMed: 11934964]
79.
Hunt RH, Lanas A, Stichtenoth DO, et al. Myths and facts in the use of anti-inflammatory drugs. Ann Med. 2009;41(6):423–37. Publication type not included in this review. [PubMed: 19430988]
80.
Ilic KV, Sefik-Bukilica M, Jankovic S, et al. Efficacy and safety of two generic copies of nimesulide in patients with low back pain or knee osteoarthritis. Reumatismo. 2009;61(1):27–33. Drug not included in this review. [PubMed: 19370185]
81.
Inotai A, Rojkovich B, Meszaros A. The assessment of oral NSAID use in patients with rheumatoid arthritis in Hungary--a cross sectional non interventional study. Acta Pharmaceutica Hungarica. 80(1):47–54. Foreign Language article. [PubMed: 20443365]
82.
Jachak SM. PGE synthase inhibitors as an alternative to COX-2 inhibitors. Curr Opin Investig Drugs. 2007;8(5):411–5. Population differs from those in this review. [PubMed: 17520870]
83.
Kawai S, Uchida E, Kondo M, et al. Efficacy and safety of ketoprofen patch in patients with rheumatoid arthritis: a randomized, double-blind, placebo-controlled study. J Clin Pharmacol. 2010;50(10):1171–9. Drug not included in this review. [PubMed: 20133510]
84.
Kivitz A, Fairfax M, Sheldon EA, et al. Comparison of the effectiveness and tolerability of lidocaine patch 5% versus celecoxib for osteoarthritis-related knee pain: post hoc analysis of a 12 week, prospective, randomized, active-controlled, open-label, parallel-group trial in adults. Clin Ther. 2008;30(12):2366–77. Outcomes not included in this review. [PubMed: 19167595]
85.
Klein G, Kullich W, Schnitker J, et al. Efficacy and tolerance of an oral enzyme combination in painful osteoarthritis of the hip. A double-blind, randomised study comparing oral enzymes with non-steroidal anti-inflammatory drugs. Clin Exp Rheumatol. 2006;24(1):25–30. Outcomes not included in this review. [PubMed: 16539815]
86.
Kroenke K, Krebs EE, Bair MJ. Pharmacotherapy of chronic pain: a synthesis of recommendations from systematic reviews. Gen Hosp Psychiatry. 2009;31(3):206–19. Population differs from those in this review. [PubMed: 19410099]
87.
Krueger K, Lino L, Dore R, et al. Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II) Ann Rheum Dis. 2008;67(3):315–22. Outcomes not included in this review. [PubMed: 17965424]
88.
Krum H, Curtis SP, Kaur A, et al. Baseline factors associated with congestive heart failure in patients receiving etoricoxib or diclofenac: multivariate analysis of the MEDAL program. Eur J Heart Fail. 2009;11(6):542–50. Outcomes not included in this review. [PubMed: 19380329]
89.
Krum H, Swergold G, Curtis SP, et al. Factors associated with blood pressure changes in patients receiving diclofenac or etoricoxib: results from the MEDAL study. J Hypertens. 2009;27(4):886–93. Outcomes not included in this review. [PubMed: 19516186]
90.
Laine L, Connors LG, Reicin A, et al. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology. 2003;124(2):288–92. Drug not included in this review. [PubMed: 12557133]
91.
Laine L, Curtis SP, Cryer B, et al. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2007;369(9560):465–73. Outcomes not included in this review. [PubMed: 17292766]
92.
Laine L, Curtis SP, Langman M, et al. Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac. Gastroenterology. 2008;135(5):1517–25. Outcomes not included in this review. [PubMed: 18823986]
93.
Laine L, Harper S, Simon T. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology. 1999;117(4):776–83. Drug not included in this review. [PubMed: 10500058]
94.
Laine L, White WB, Rostom A, et al. COX-2 selective inhibitors in the treatment of osteoarthritis. Semin Arthritis Rheum. 2008;38(3):165–87. Population differs from those in this review. [PubMed: 18177922]
95.
Lazebnik LB, Drozdov VN, Li IA, et al. Celecoxib and Tramadol as an alternative osteoarthrosis therapy in patients with NSAID gastropathy. Eksp Klin Gastroenterol. 2004;(5):21–5. Foreign Language article. [PubMed: 15770856]
96.
Lehmann R, Brzosko M, Kopsa P, et al. Efficacy and tolerability of lumiracoxib 100 mg once daily in knee osteoarthritis: a 13-week, randomized, double-blind study vs. placebo and celecoxib. Curr Med Res Opin. 2005;21(4):517–26. Drug not included in this review. [PubMed: 15899100]
97.
Lems WF, Bijlsma JWJ. Efficacy of dietary supplements in patients with osteoarthritis: The doubt persists. Ned Tijdschr Geneeskd. 2006;150(20):1105–7. Foreign Language article. [PubMed: 16756221]
98.
Levy RM, Saikovsky R, Shmidt E, et al. Flavocoxid is as effective as naproxen for managing the signs and symptoms of osteoarthritis of the knee in humans: a short-term randomized, double-blind pilot study. Nutr Res. 2009;29(5):298–304. Outcomes not included in this review. [PubMed: 19555810]
99.
Lin H-Y, Cheng T-T, Wang J-H, et al. Etoricoxib improves pain, function and quality of life: results of a real-world effectiveness trial. Int J Rheum Dis. 2010;13(2):144–50. Drug not included in this review. [PubMed: 20536599]
100.
Lodato F, Azzaroli F, Turco L, et al. Adverse effects of proton pump inhibitors. Best Pract Res Clin Gastroenterol. 2010;24(2):193–201. Publication type not included in this review. [PubMed: 20227032]
101.
MacDonald TM, Reginster JY, Littlejohn TW, et al. Effect on blood pressure of lumiracoxib versus ibuprofen in patients with osteoarthritis and controlled hypertension: a randomized trial. J Hypertens. 2008;26(8):1695–702. Outcomes not included in this review. [PubMed: 18622250]
102.
Martel-Pelletier J, Kwan Tat S, Pelletier JP. Effects of chondroitin sulfate in the pathophysiology of the osteoarthritic joint: a narrative review. Osteoarthritis Cartilage. 2010;18(Suppl 1):S7–11. Publication type not included in this review. [PubMed: 20399897]
103.
Marti-Bonmati L, Sanz-Requena R, Rodrigo JL, et al. Glucosamine sulfate effect on the degenerated patellar cartilage: preliminary findings by pharmacokinetic magnetic resonance modeling. Eur Radiol. 2009;19(6):1512–8. Outcomes not included in this review. [PubMed: 19214525]
104.
Massey T, Derry S, Moore AR, et al. Topical NSAIDs for acute pain in adults. Cochrane Database Syst Rev. 2010;(6) Population differs from those in this review. [PMC free article: PMC4163964] [PubMed: 20556778]
105.
Mateos JL. Selective inhibitors of cyclooxygenase-2 (COX-2), celecoxib and parecoxib: a systematic review. Drugs Today (Barc) 46(Suppl A):1–25. Foreign Language article. [PubMed: 20224826]
106.
May M, Benghuzzi H, Tucci M, et al. The role of glucosamine, chondroitin and thymoquinone on the viability and proliferation of a HTB–93 rheumatoid arthritis cell model. Biomed Sci Instrum. 2006;42:338–43. Population differs from those in this review. [PubMed: 16817631]
107.
Mazieres B, Combe B, Phan Van A, et al. Chondroitin sulfate in osteoarthritis of the knee: a prospective, double-blind, placebo-controlled multicenter clinical study. J Rheumatol. 2001;(28):466–72. Study results included through another publication. [PubMed: 11196521]
108.
Mazziotti G, Canalis E, Giustina A. Drug-induced Osteoporosis: Mechanisms and Clinical Implications. Am J Med. 2010;123(10):877–84. Publication type not included in this review. [PubMed: 20920685]
109.
Medhi B, Kishore K, Singh U, et al. Comparative clinical trial of castor oil and diclofenac sodium in patients with osteoarthritis. Phytother Res. 2009;23(10):1469–73. Outcomes not included in this review. [PubMed: 19288533]
110.
Mehta K, Gala J, Bhasale S, et al. Comparison of glucosamine sulfate and a polyherbal supplement for the relief of osteoarthritis of the knee: a randomized controlled trial [ISRCTN25438351] BMC Complement Altern Med. 2007;7(34) Drug not included in this review. [PMC free article: PMC2131759] [PubMed: 17974032]
111.
Mejersjo C, Wenneberg B. Diclofenac sodium and occlusal splint therapy in TMJ osteoarthritis: a randomized controlled trial. J Oral Rehabil. 2008;35(10):729–38. Outcomes not included in this review. [PubMed: 18482350]
112.
Meunier A, Aspenberg P, Good L. Celecoxib does not appear to affect prosthesis fixation in total knee replacement: A randomized study using radiostereometry in 50 patients. Acta Orthopaedica. 2009;80(1):46–50. Drug not included in this review. [PMC free article: PMC2823240] [PubMed: 19234885]
113.
Monfort J, Martel-Pelletier J, Pelletier JP. Chondroitin sulphate for symptomatic osteoarthritis: critical appraisal of meta-analyses. Curr Med Res Opin. 2008;24(5):1303–8. Publication type not included in this review. [PubMed: 18416884]
114.
Montine TJ, Sonnen JA, Milne G, et al. Elevated ratio of urinary metabolites of thromboxane and prostacyclin is associated with adverse cardiovascular events in ADAPT. PLoS ONE [Electronic Resource] 2010;5(2):e9340. Study design not included in this review. [PMC free article: PMC2824826] [PubMed: 20174466]
115.
Moore RA, Derry S, McQuay HJ. Single dose oral acemetacin for acute postoperative pain in adults. Cochrane Database Syst Rev. 2009. Drug not included in this review. [PMC free article: PMC4170991] [PubMed: 19588437]
116.
Moore RA, Derry S, McQuay HJ. Single dose oral dexibuprofen [S(+)-ibuprofen] for acute postoperative pain in adults. Cochrane Database Syst Rev. 2009. Drug not included in this review. [PMC free article: PMC4170892] [PubMed: 19588434]
117.
Moore RA, Derry S, McQuay HJ. Single dose oral meloxicam for acute postoperative pain in adults. Cochrane Database Syst Rev. 2009. Drug not included in this review. [PMC free article: PMC4175538] [PubMed: 19821429]
118.
Moore RA, Derry S, McQuay HJ. Single dose oral sulindac for acute postoperative pain in adults. Cochrane Database Syst Rev. 2009. Drug not included in this review. [PMC free article: PMC4170893] [PubMed: 19821425]
119.
Moore RA, Derry S, Moore M, et al. Single dose oral nabumetone for acute postoperative pain in adults. Cochrane Database Syst Rev. 2009;(4):CD007548. Drug not included in this review. [PMC free article: PMC4170900] [PubMed: 19821428]
120.
Morreale P, Manopulo R, Galati M, et al. Comparison of the antiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis. J Rheumatol. 1996;23(8):1385–91. Study results included through another publication. [PubMed: 8856618]
121.
Muniyappa R, Karne RJ, Hall G, et al. Oral glucosamine for 6 weeks at standard doses does not cause or worsen insulin resistance or endothelial dysfunction in lean or obese subjects. Diabetes. 2006;55(11):3142–50. Outcomes not included in this review. [PubMed: 17065354]
122.
Nakamura H, Masuko K, Yudoh K, et al. Effects of glucosamine administration on patients with rheumatoid arthritis. Rheumatol Int. 2007;27(3):213–8. Population differs from those in this review. [PubMed: 16953394]
123.
Noack W, Fischer M, Forster K, et al. Glucosamine sulfate in osteoarthritis of the knee. Osteoarthritis Cartilage. 1994;(2):51–9. Study results included through another publication. [PubMed: 11548224]
124.
Oztuna V, Eskandari M, Bugdayci R, et al. Intra-articular injection of tenoxicam in osteoarthritic knee joints with effusion. Orthopedics. 2007;30(12):1039–42. Outcomes not included in this review. [PubMed: 18198776]
125.
Pareek A, Chandanwale AS, Oak J, et al. Efficacy and safety of aceclofenac in the treatment of osteoarthritis: a randomized double-blind comparative clinical trial versus diclofenac - an Indian experience. Curr Med Res Opin. 2006;22(5):977–88. Drug not included in this review. [PubMed: 16709320]
126.
Paul S, Das N, Ghosh S. The effects of aceclofenac and nabumetone in osteoarthritis. JNMA. 2009;48(174):121–5. Drug not included in this review. [PubMed: 20387351]
127.
Pavelka K, Gatterova J, Olejarova M, et al. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med. 2002;162(18):2113–23. Study results included through another publication. [PubMed: 12374520]
128.
Pavelka K, Recker DP, Verburg KM. Valdecoxib is as effective as diclofenac in the management of rheumatoid arthritis with a lower incidence of gastroduodenal ulcers: results of a 26-week trial. Rheumatology (Oxford) 2003;42(10):1207–15. Drug not included in this review. [PubMed: 12810937]
129.
Peeva E, Beals CR, Bolognese JA, et al. A walking model to assess the onset of analgesia in osteoarthritis knee pain. Osteoarthritis Cartilage. 2010;18(5):646–53. Drug not included in this review. [PubMed: 20175977]
130.
Petersen SG, Saxne T, Heinegard D, et al. Glucosamine but not ibuprofen alters cartilage turnover in osteoarthritis patients in response to physical training. Osteoarthritis Cartilage. 2010;18(1):34–40. Outcomes not included in this review. [PubMed: 19679221]
131.
Petrov VI, Babaeva AR, Cherevkova EV, et al. Efficiency of potentiated antibodies to tumor necrosis factor-alpha (Artrofoon) in the therapy of patients with rheumatoid arthritis. Bull Exp Biol Med. 2003;135(Suppl 7):155–8. Outcomes not included in this review. [PubMed: 12949686]
132.
Pujalte J, Liavore E, Ylescupidez F. Double-blind clinical evaluation of oral glucosamine sulphate in the basic treatment of osteoarthritis. Curr Med Res Opin. 1980;(7):110–4. Study results included through another publication. [PubMed: 7002479]
133.
Puopolo A, Boice JA, Fidelholtz JL, et al. A randomized placebo-controlled trial comparing the efficacy of etoricoxib 30 mg and ibuprofen 2400 mg for the treatment of patients with osteoarthritis. Osteoarthritis Cartilage. 2007;15(12):1348–56. Outcomes not included in this review. [PubMed: 17631392]
134.
Rahme E, Bernatsky S. NSAIDs and risk of lower gastrointestinal bleeding. Lancet. 2010;376(9736):146–8. Publication type not included in this review. [PubMed: 20638554]
135.
Raynauld JP, Martel-Pelletier J, Bias P, et al. Protective effects of licofelone, a 5-lipoxygenase and cyclo-oxygenase inhibitor, versus naproxen on cartilage loss in knee osteoarthritis: a first multicentre clinical trial using quantitative MRI. Ann Rheum Dis. 2009;68(6):938–47. Outcomes not included in this review. [PubMed: 18653484]
136.
Reginster J, Derosy R, Rovati L. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomized, placebo-controlled clinical trial. Lancet. 2001;(357):251–6. Study results included through another publication. [PubMed: 11214126]
137.
Reginster JY, Malmstrom K, Mehta A, et al. Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomised studies of patients with osteoarthritis. Ann Rheum Dis. 2007;66(7):945–51. Outcomes not included in this review. [PMC free article: PMC1955093] [PubMed: 17142385]
138.
Reiter S. Evidence-based evaluation of study results of symptomatic glucosamine therapy. Zeitschrift fur Rheumatologie. 2005;64(7):456–66. Foreign Language article. [PubMed: 16244829]
139.
Renda G, Zurro M, Romano M, et al. Aspirin-triggered lipoxin in patients treated with aspirin and selective vs. nonselective COX-2 inhibitors. Br J Clin Pharmacol. 2010;69(3):303–6. Outcomes not included in this review. [PMC free article: PMC2829701] [PubMed: 20233202]
140.
Richards JB, Joseph L, Schwartzman K, et al. The effect of cyclooxygenase-2 inhibitors on bone mineral density: results from the Canadian Multicentre Osteoporosis Study. Osteoporos Int. 2006;17(9):1410–9. Outcomes not included in this review. [PubMed: 16791706]
141.
Richy F, Rabenda V, Mawet A, et al. Flurbiprofen in the symptomatic management of rheumatoid arthritis: a valuable alternative. Int J Clin Pract. 2007;61(8):1396–406. Population differs from those in this review. [PubMed: 17596188]
142.
Rindone J, Hiller D, Callacott E, et al. Randomized, controlled trial of glucosamine for treating osteoarthritis of the knee. West J Med. 2000;172(2):91–4. Study results included through another publication. [PMC free article: PMC1070762] [PubMed: 10693368]
143.
Rosenberg JA, Goldstein JL. Safety and efficacy of lumiracoxib compared with NSAIDs. Nat Clin Pract Gastroenterol Hepatol. 2005;2(1):14–5. Population differs from those in this review. [PubMed: 16265092]
144.
Ross SM. Osteoarthritis: a proprietary Arnica gel is found to be as effective as ibuprofen gel in osteoarthritis of the hands. Holist Nurs Pract. 2008;22(4):237–9. Outcomes not included in this review. [PubMed: 18607237]
145.
Rozenberg S, Meric G, Jeanpetit Y. Changes in quality of life in patients with osteoarthritis treated with celecoxib: the Qualice study. Presse Medicale. 2008;37(4 Pt 1):571–8. Foreign Language article. [PubMed: 18206341]
146.
Rozendaal RM, Uitterlinden EJ, van Osch GJVM, et al. Effect of glucosamine sulphate on joint space narrowing, pain and function in patients with hip osteoarthritis;subgroup analyses of a randomized controlled trial. Osteoarthritis & Cartilage. 2009;17(4):427–32. Study results included through another publication. [PubMed: 18848470]
147.
Ruane R, Griffiths P. Glucosamine therapy compared to ibuprofen for joint pain. Br J Community Nurs. 2002;7(3):148–52. Study results included through another publication. [PubMed: 11904551]
148.
Saag K, van der Heijde D, Fisher C, et al. Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs: a 6-week and a 1-year trial in patients with osteoarthritis. Osteoarthritis Studies Group. Arch Fam Med. 2000;9(10):1124–34. Drug not included in this review. [PubMed: 11115219]
149.
Scheiman JM, Hindley CE. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events. Clin Ther. 2010;32(4):667–77. Publication type not included in this review. [PubMed: 20435236]
150.
Schnitzer TJ, Kivitz AJ, Lipetz RS, et al. Comparison of the COX-inhibiting nitric oxide donator AZD3582 and rofecoxib in treating the signs and symptoms of Osteoarthritis of the knee. Arthritis Rheum. 2005;53(6):827–37. Outcomes not included in this review. [PubMed: 16342089]
151.
Schnitzer TJ, Tesser JR, Cooper KM, et al. A 4-week randomized study of acetaminophen extended-release vs rofecoxib in knee osteoarthritis. Osteoarthritis Cartilage. 2009;17(1):1–7. Outcomes not included in this review. [PubMed: 18640856]
152.
Silverstein F, Simon L, Faich G. Reporting of 6-month vs 12-month data in a clinical trial of celecoxib. In reply. JAMA. 2001;286(19):2399–400. Publication type not included in this review. [PubMed: 11712924]
153.
Simon L, Weaver AL, Graham DY, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA. 1999;282(20):1921–8. Study results included through another publication. [PubMed: 10580457]
154.
Smugar SS, Schnitzer TJ, Weaver AL, et al. Rofecoxib 12.5 mg, rofecoxib 25 mg, and celecoxib 200 mg in the treatment of symptomatic osteoarthritis: results of two similarly designed studies. Curr Med Res Opin. 2006;22(7):1353–67. Outcomes not included in this review. [PubMed: 16834834]
155.
Solomon DH, Rassen JA, Glynn RJ, et al. The comparative safety of analgesics in older adults with arthritis. Arch Intern Med. 2010;170(22):1968–76. Drug not included in this review. [PubMed: 21149752]
156.
Song YW, Lee EY, Koh E-M, et al. Assessment of comparative pain relief and tolerability of SKI306X compared with celecoxib in patients with rheumatoid arthritis: a 6-week, multicenter, randomized, double-blind, double-dummy, phase III, noninferiority clinical trial. Clin Ther. 2007;29(5):862–73. Outcomes not included in this review. [PubMed: 17697905]
157.
Stumpf JL, Lin SW. Effect of glucosamine on glucose control. Ann Pharmacother. 2006;40(4):694–8. Outcomes not included in this review. [PubMed: 16569816]
158.
Tirunagari SK, Derry S, Moore RA, et al. Single dose oral etodolac for acute postoperative pain in adults. Cochrane Database Syst Rev. 2009;(3):CD007357. Drug not included in this review. [PMC free article: PMC4164827] [PubMed: 19588426]
159.
Uebelhart D, Thonar E, Delmas P, et al. Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. Osteoarthritis Cartilage. 1998;6:39–46. Study results included through another publication. [PubMed: 9743819]
160.
Underwood M, Ashby D, Carnes D, et al. Topical or oral ibuprofen for chronic knee pain in older people. The TOIB study. Health Technol Assess. 2008;12(22):iii–iv. ix–155. Study results included through another publication. [PubMed: 18505668]
161.
USFDA. Vioxx gastrointestinal safety, FDA Advisory Committee Briefing Document NDA 21-042, s007 2001. Feb 8, 2001. Drug not included in this review.
162.
USFDA. Labeling changes for arthritis drug Celebrex, FDA Talk Paper T02-24 2002. Dec 6, 2005. Publication type not included in this review.
163.
Verkleij SP, Luijsterburg PA, Koes BW, et al. Effectiveness of diclofenac versus acetaminophen in primary care patients with knee osteoarthritis: [NTR1485], DIPA-trial: design of a randomized clinical trial. BMC Musculoskelet Disord. 2010;11(7):2010. Outcomes not included in this review. [PMC free article: PMC2835660] [PubMed: 20067607]
164.
Wagenitz A, Mueller EA, Frentzel A, et al. Comparative efficacy and tolerability of two sustained-release formulations of diclofenac: results of a double-blind, randomised study in patients with osteoarthritis and a reappraisal of diclofenac’s use in this patient population. Curr Med Res Opin. 2007;23(8):1957–66. Drug not included in this review. [PubMed: 17631698]
165.
Wangroongsub Y, Tanavalee A, Wilairatana V, et al. Comparable clinical outcomes between glucosamine sulfate-potassium chloride and glucosamine sulfate sodium chloride in patients with mild and moderate knee osteoarthritis: a randomized, double-blind study. J Med Assoc Thai. 2010;93(7):805–11. Drug not included in this review. [PubMed: 20649060]
166.
Weaver AL, Messner RP, Storms WW, et al. Treatment of patients with osteoarthritis with rofecoxib compared with nabumetone. J Clin Rheumatol. 2006;12(1):17–25. Outcomes not included in this review. [PubMed: 16484875]
167.
White WB, Schnitzer TJ, Fleming R, et al. Effects of the cyclooxygenase inhibiting nitric oxide donator naproxcinod versus naproxen on systemic blood pressure in patients with osteoarthritis. Am J Cardiol. 2009;104(6):840–5. Outcomes not included in this review. [PubMed: 19733721]
168.
Widrig R, Suter A, Saller R, et al. Choosing between NSAID and arnica for topical treatment of hand osteoarthritis in a randomised, double-blind study. Rheumatol Int. 2007;27(6):585–91. Outcomes not included in this review. [PubMed: 17318618]
169.
Wiesenhutter CW, Boice JA, Ko A, et al. Evaluation of the comparative efficacy of etoricoxib and ibuprofen for treatment of patients with osteoarthritis: A randomized, double-blind, placebo-controlled trial. Mayo Clinic; Mayo Clinic proceedings; 2005. pp. 470–9. Outcomes not included in this review. [PubMed: 15819283]
170.
Williams GW, Kivitz AJ, Brown MT, et al. A comparison of valdecoxib and naproxen in the treatment of rheumatoid arthritis symptoms. Clin Ther. 2006;28(2):204–21. Outcomes not included in this review. [PubMed: 16678642]
171.
Wittenberg RH, Schell E, Krehan G, et al. First-dose analgesic effect of the cyclo-oxygenase-2 selective inhibitor lumiracoxib in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled comparison with celecoxib. Arthritis Res Ther. 2006;8(2):R35. Outcomes not included in this review. [PMC free article: PMC1526611] [PubMed: 16469112]
172.
Woldanska-Okonska M, Miecznik A, Czernicki J, et al. The double blind evaluation of the magnetophoresis efficacy (a new method of the drug application through skin) with the application of 2.5% ketoprofenum-gel in patients with gonarthrosis. Postepy Rehabilitacji. 2006;20(3):11–6. Foreign Language article.
173.
Zammit GV, Menz HB, Munteanu SE, et al. Interventions for treating osteoarthritis of the big toe joint. Cochrane Database Syst Rev. 2010;(8) Drug not included in this review. [PubMed: 20824867]
174.
Zehetgruber H, Grubl A, Goll A, et al. Prevention of heterotopic ossification after THA with indomethacin: analysis of risk factors. Zeitschrift fur Orthopadie und Ihre Grenzgebiete. 2005;143(6):631–7. Foreign Language article. [PubMed: 16380894]
175.
Zhang HM, Min ZH, Zhang ZQ, et al. Effect of Chinese medicine treatment according to syndrome differentiation on proteoglycan levels in the synovial fluid of knee osteoarthritis: randomized control study. Journal of Clinical Rehabilitative Tissue Engineering Research. 2008;12(20):3962–5. Foreign Language article.
176.
Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthritis Cartilage. 2007;15(9):981–1000. Population differs from those in this review. [PubMed: 17719803]
177.
Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage. 2008;16(2):137–62. Population differs from those in this review. [PubMed: 18279766]
178.
Zhang YX, Dong W, Liu H, et al. Effects of chondroitin sulfate and glucosamine in adult patients with Kaschin-Beck disease. Clin Rheumatol. 2010;29(4):357–62. Population differs from those in this review. [PubMed: 20108108]
Cover of Analgesics for Osteoarthritis
Analgesics for Osteoarthritis: An Update of the 2006 Comparative Effectiveness Review [Internet].
Comparative Effectiveness Reviews, No. 38.
Chou R, McDonagh MS, Nakamoto E, et al.

Download

AHRQ (US Agency for Healthcare Research and Quality)

PubMed Health Blog...

read all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...